Lymphomas | Clinical

A 71-Year-Old Woman with Relapsed/Refractory DLBCL

April 19, 2021

Matthew Lunning, DO, presents a case study of a 71-year-old woman with relapsed/refractory diffuse large B-cell lymphoma.

Pirtobrutinib Shows Favorable Efficacy and Safety in Mantle Cell Lymphoma

April 15, 2021

Pirtobrutinib showed promising efficacy and safety as treatment of patients with mantle cell lymphoma, demonstrating the potential to serve an unmet medical need.

Phase 3 Study Supports Pembrolizumab in Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma

April 14, 2021

The interim analysis from the phase 3 KEYNOTE-204 study suggests pembrolizumab should be considered the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma over brentuximab vedotin.

Findings Continue to Show Brentuximab Vedotin Plus CHP Offers Survival Advantage in PTCL

April 14, 2021

Andrew M. Evens, DO, MSc, considered the data supporting brentuximab vedotin with chemotherapy for the treatment of a patient with peripheral T-cell lymphoma.

CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHL

April 12, 2021

Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.

Copanlisib Plus Rituximab Extends Progression-Free Survival in Indolent NHL

April 10, 2021

Primary results from the phase 3 CHRONOS-3 study revealed a survival benefit with the combination of copanlisib in combination with rituximab over rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

Novel Combinations Excite the R/R Hodgkin Lymphoma Treatment Landscape

April 08, 2021

While the treatment of relapsed or refractory Hodgkin lymphoma has seen novel approaches in recent years improving outcomes for many patients, high-risk patients develop progressive disease and have limited treatment options.

Tuscano Reviews Treatment and Toxicity Management for a Patient With Classic Hodgkin Lymphoma

April 05, 2021

Assessing prognosis is an important step prior to treatment selection for a patient with classic Hodgkin lymphoma, explained Joseph Michael Tuscano, MD. Other steps aid in the treatment and management of toxicity.

Toxicities From Tafasitamab Monotherapy Are Less Severe After Discontinuing Lenalidomide in R/R DLBCL

April 04, 2021

The NCCN guidelines options available for patients with relapsed/refractory DLBCL include gemcitabine/oxaliplatin with or without rituximab, polatuzumab vedotin with or without bendamustine and rituximab, or the combination of bendamustine and rituximab alone.

Phase 2 Trial of Parsaclisib Shows Efficacy in Marginal Zone Lymphoma

March 27, 2021

Tycel J. Phillips, MD, discusses the design and responses at 8 weeks in a phase 2 trial of parsaclisib in patients with relapsed/refractory marginal zone lymphoma.